HC Wainwright Brokers Decrease Earnings Estimates for ASMB

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Equities researchers at HC Wainwright decreased their Q1 2026 EPS estimates for shares of Assembly Biosciences in a research report issued to clients and investors on Thursday, March 26th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.50). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at $3.51 EPS, FY2026 earnings at $1.61 EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at $0.32 EPS and FY2029 earnings at ($2.83) EPS.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share for the quarter, beating the consensus estimate of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The business had revenue of $42.47 million for the quarter, compared to the consensus estimate of $7.42 million.

Several other equities analysts have also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Wall Street Zen raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.75.

Assembly Biosciences Stock Up 4.2%

NASDAQ ASMB opened at $27.75 on Monday. The stock has a market capitalization of $440.20 million, a P/E ratio of -37.50 and a beta of 1.11. Assembly Biosciences has a 52-week low of $7.75 and a 52-week high of $39.71. The firm has a 50-day moving average price of $27.89 and a 200 day moving average price of $29.91.

Institutional Trading of Assembly Biosciences

A number of institutional investors have recently added to or reduced their stakes in ASMB. Bank of America Corp DE increased its holdings in Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Assembly Biosciences during the 4th quarter valued at approximately $147,000. Acadian Asset Management LLC boosted its stake in shares of Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,823 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of Assembly Biosciences in the 4th quarter worth approximately $228,000. Finally, Virtus Investment Advisers LLC acquired a new stake in shares of Assembly Biosciences in the 4th quarter worth approximately $251,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.